Imatinib revolutionized gastrointestinal stromal tumor (GIST) treatment but median-progression-free-survival of unresectable/metastatic disease is , 2 y. B-RAF V600 -mutated-melanoma responds to vemurafenib dramatically but median-progression-free-survival is , 9 mo. Combining imatinib with immunotherapy (peginterferon a-2b) in GIST showed significant induction of antitumor immunity and highly promising clinical outcomes. This strategy warrants further testing in other malignancies.
Imatinib (IM, Gleevec

1
, Glivec 1 ), 1 a selective inhibitor of ABL, KIT and PDGFRA/B, represents the first paradigmshift targeted therapy for gastrointestinal stromal tumor (GIST). Unfortunately, the median-progression-free-survival (PFS) of unresectable locally advanced and metastatic GIST is , 2 y. 2 Vemurafenib (PLX4032/ RG7204) demonstrated response rate of 52%, and represents a similar paradigmshift treatment for B-RAF V600 -mutatedmelanoma, however, the short median-PFS of , 9 mo is disappointing. 3 Common drug-resistant mechanisms include: (1) Mutation of target evading drug binding, (2) Upregulation of up-or down-stream signaling molecule(s), (3) Alternative pathway(s) bypassing target. The first mechanism dominates IM-resistance in GIST with missense KIT mutations commonly located in KIT kinase domain 4 and activation loop. A single amino acid replacement (gatekeeper mutations) is sufficient to alter hydrogen bonds, or hydrophobic support, thus impede drug binding (Fig. 1A-C) . Although gatekeeper mutations in B-RAF can confer vemurafenib-resistance in laboratory models, so far vemurafenib-resistance in melanoma manifested mainly receptortyrosine kinase or N-RAS upregulation, or signaling pathway switch to PDFGRB overexpression. 5 Drug-resistant clones evolve continuously and the poorly-understood resilient cancer stem-cells repopulate continuously; they represent the main culprits of relapse. The vulnerability of developing drugresistance using monotherapy (Fig. 1A-C ) and the nature of these two culprits prompted us to exploit antitumor immunity to overcome relapse by investigating a new strategy of combining targeted therapy (IM) with immunotherapy (peginterferon a-2b [PegIntron 1 ]) in GIST. 6 Our results show that this combination treatment is well tolerated, safe, and induced significant IFNc-producing-CD8 + , -CD4 + , -NK cell, and robust IFNc-producingtumor-infiltrating-lymphocytes, signifying induction of innate and Th1 adaptive cell-mediated immunity (Th1 response). 6 Complete remission (CR) + partial response (PR) = 100%; overall survival = 100%; one patient died of unrelated illness while in radiographic near-CR; after a median follow-up of 3.9 y, five of the seven evaluable patients are in continuing PR/CR with duration . doubling the median-genotype-specific-PFS of the Phase III IM-monotherapy trial
Pt#6 developed IM-resistance, but when peginterferon a-2b was re-initiated, a second PR was induced, indicative of recall of antitumor immunity. 6 Interferon a (IFNa) is a Type 1 IFN, a physiological danger signal (3rd signal) and immune modulator. ). Our highly promising clinical outcome (Fig. 1D) testifies that IFNa successfully modulates steps 2-10 toward antitumor response during combination treatment. 6 Monoclonal antibodies (mAb) against cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4) (e.g., ipilimumab) can modulate step 4, and mAb against programmed cell death 1 pathway (PD-L1/PD-1) (e.g., MDX-1105) can modulate steps 8 and 10, and represent promising immune modulators to enhance CTL functions, but their adverse effects remains unknown contrasting the 5 years' experience with IFNa.
Effective, non-marrow suppressive, minimally toxic treatment modalities constitute "targeted therapy" in the broad sense, which includes targeted small molecule inhibitors, hormone receptor agonist/ antagonists, and monoclonal antibodies. Advances in tumor biology undoubtedly will lead to discovery of more effective targeted therapeutic agents in the future, but drug-resistance and early relapse will undoubtedly maintain recurrent themes using monotherapy. We combined peginterferon a-2b (an immune modulator and a danger signal) with IM (non-marrow suppressive and effective in tumor killing to provide 1st and 2nd signals) in GIST model, demonstrated significant induction of innate and Th1 response along with highly promising clinical outcome 6 ( Fig. 1D) , and we plan to incorporate the insights gained into future larger trials. We believe this mew strategy may benefit large number of different subtypes of cancer patients. Currently, many malignancies have encouraging suitable "targeted" drugs to achieve simultaneous PR/CR and antitumor immunity if combined with immunotherapy (peginterferon a). The short PFS of vemurafenib-treated B-RAF V600 -mutated-melanoma 3 may be improved by combination with peginterferon a (immunotherapy) and warrant a trial. Another example is to combine oxaliplatin 10 (or irinotecan) with peginterferon a for colorectal cancer with one precaution-careful dosing of chemotherapeutic agents to avoid leukopenia, which is detrimental to DC differentiation toward Th1 response. Some other very encouraging examples to combine with peginterferon a (immunotherapy) and warrant testing include leuprolide and or bicalutamide for prostate cancer, tamoxifen or aromatase inhibitors for ER + PR + breast cancer, lapatinib for ER + HER2
+ breast cancer, trastuzumab for HER2 + breast cancer, erlotinib or crizotinib for non-small cell lung cancers harboring EGFR mutations or EML4-ALK fusion gene respectively, and radiation therapy for radio-sensitive tumors (i.e., seminomas, Ewing sarcoma, lymphoma). Pts#1, 2, 4, 5, 8) , much improved comparing to the median-genotype-specific-PFS of Phase III S0033 IM monotherapy trial (yellow bars). Pt#3 presented with Stage IV aggressive GIST harboring KIT exon 11 deletion, extensive liver metastasis, mitotic figure $ 40/high power field, had swift excellent response achieving PR within 8 weeks, but progressed with PFS slightly longer than two years. Pt#6 developed IM-resistance, and re-initiation of peginterferon a-2b resulted in second PR. Pt#6 progressed again while off all treatment, and combination treatment of sunitinib plus peginterferon a-2b resulted in stable disease (B, last column).
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